Search NLS News

Swedish Orphan Biovitrum (Sobi) has entered into an agreement and plan of merger with CTI BioPharma (CTI) under which Sobi has agreed to acquire CTI, by means of a tender offer. Sobi is to commence a cash tender offer to acquire all issued and outstanding shares of CTI for USD 9.10 per share, corresponding to […]

Carolyn Bertozzi, currently Anne T. And Robert M. Bass Professor at Stanford University, CA. USA, was awarded one of the three Nobel Prizes in Chemistry 2022.

Salipro Biotech and DyNAbind have announced the achievement of a key milestone from their collaboration. The collaboration combines Salipro Biotech’s platform technology for membrane proteins with DyNAbind’s DNA-Encoded Library (DEL) technology to accelerate the development of novel drugs for challenging targets. Membrane proteins like GPCRs, SLC transporters and Ion Channels are an important but difficult-to-drug […]

Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. “Koselugo offers hope for children whose quality of life and overall well-being is impacted by the growth of painful, debilitating tumours throughout the body. We are […]

Cantargia has announced a successful safety review of the ten non-squamous non-small cell lung cancer (NSCLC) patients treated with its lead asset nadunolimab (CAN04) and carboplatin/pemetrexed in the phase I/IIa CANFOUR trial. Enrollment to this trial has now ended; continued development of nadunolimab in NSCLC will further focus on patient subgroups by implementation of a […]

Swedish Neogap and the Zurich-based company Cellerys has entered a collaboration related to Phase II study of a new therapy for multiple sclerosis. Cellerys will use Neogap’s patented EpiTCer technology in its upcoming Phase II study of a new type of cell therapy aimed at inducing antigen-specific immune tolerance in patients with multiple sclerosis (MS). […]

The agreement focuses on activators of KCNQ2, an ion channel that has been clinically validated as a target for the treatment of epilepsy. Clinical findings suggest that activation of KCNQ2 channels may provide treatment options for other types of neurological disorders including rare forms of epilepsy. Read more: Lundbeck and Alloy Therapeutics collaborate Under the […]

A second planned interim analysis has been conducted of the ongoing clinical phase 1b study with the company’s vaccine candidate ALZ-101 against Alzheimer’s disease. The analysis shows positive data with continued good safety and tolerability as well as a clear immunological response, that is, that specific antibodies have been formed, states the company. Based on […]

KLIFO has announced that Alejandra Mørk has taken the decision to step down as CEO and the company has appointed Rasmus Nelund as the new CEO. Alejandra Mørk will step into a new role as senior client advisor and Board member. Two years ago, a new phase in KLIFO’s development journey began when Alejandra Mørk […]

Professor Åslaug Helland is the recipient of the King Olav Vs Cancer Research Award 2023. “This is a great honor, and I am very happy about this recognition of the research environment involved. I have been very fortunate working with lots of very talented people over the years!” Helland commented to Oslo Cancer Cluster. The […]